CT-Guided Adaptive Radiotherapy for the Treatment of Technically Challenging Oligometastatic Disease: A Case Report.

There is a growing interest in the application of stereotactic body radiotherapy (SBRT) for the treatment of oligometastatic cancers. This increasing appeal of SBRT has highlighted the need for more sophisticated radiotherapy techniques that allow high doses of radiation to be delivered to multiple sites while limiting the exposure of neighboring healthy tissue. A major obstacle to achieving this aim has been the occurrence of interfraction target variability: the tendency of both the tumor and the surrounding tissue to undergo day-to-day non-synchronous shifts in position. Such changes in the conformation of the tumor field often compromise the effectiveness of conventional SBRT prescribed for a fixed target. We report a case of oligometastatic pelvic disease where the challenge of an unusually mobile tumor was overcome with the use of a novel technique employing cone beam CT (CBCT)-based online adaptive radiotherapy (OART). The Phase I "Adaptive Radiation for Abdominopelvic Metastases (ARAM)" clinical trial was designed to determine if OART can achieve dosing targets superior to those attained using conventional radiotherapy techniques. In this case, CT adaptive planning enabled the treatment of a pelvic target prescribed per protocol to 45Gy that would otherwise have not been amenable to treatment with conventional SBRT planning. Adaptive plans showed significant improvements in target coverage while respecting critical organ constraints, resulting in a total treatment V35Gy of 89.3% and V45Gy of 52.8%, whereas the scheduled plan would have achieved V35Gy of 67.4% and V45Gy of 13.6%. Treatment times were variable (38.1-96.7 mins), and correlated with the magnitude of daily translation which ranged from 4 to 7 cm of total linear translation. The patient tolerated treatment without any adverse events. These results demonstrate a novel application of CBCT-guided OART that allowed for the administration of ablative treatment to an unexpectedly mobile target unamenable to conventional SBRT. CBCT-guided OART currently requires increased treatment time, a need which might be reduced by optimization of daily contouring. The phase 1 clinical trial NCT05880667 is ongoing and may provide further evidence that CBCT-guided OART can meet the technical challenges posed by radiotherapy for oligometastatic abdominal and pelvic disease.